Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steve V Edelman

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The Journal of Family Practice|October 10, 2017
Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor AgonistsSteve V Edelman
Diabetes Technology & Therapeutics|February 1, 2026
Overcoming Therapeutic Inertia with Inhaled Insulin TherapyThomas C Blevins, Steve V Edelman
Nature Clinical Practice. Endocrinology & Metabolism|April 25, 2007
Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?Steve V Edelman, Satish Garg, Orville G Kolterman
Diabetes Care|November 22, 2014
Response to comment on Edelman et al. AUTONOMY: the first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetes. Diabetes Care 2014;37:2132-2140Steve V Edelman, Rong Liu, Jennal Johnson, et al.
Diabetes Care|April 19, 2014
AUTONOMY: the first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetesSteve V Edelman, Rong Liu, Jennal Johnson, et al.
The Diabetes Educator|December 14, 2018
Reference Guide for Integrating Continuous Glucose Monitoring Into Clinical PracticeDavida F Kruger, Steve V Edelman, Deborah A Hinnen, et al.
Diabetes Technology & Therapeutics|February 1, 2026
Dosing Afrezza: It's Not that ComplicatedSteve V Edelman, Thomas C Blevins, Christopher G Parkin, et al.
Diabetes, Obesity & Metabolism|May 29, 2025
Risk of new-onset type 1 diabetes in individuals with celiac disease and thyroid disease-An observational studySteve V Edelman, Daniel Agardh, Nancy Cui, et al.
Diabetes, Obesity & Metabolism|October 20, 2022
Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trialTadej Battelino, Thomas Danne, Steve V Edelman, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Journal of Family Practice|October 10, 2017
Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor AgonistsSteve V Edelman
Diabetes Technology & Therapeutics|February 1, 2026
Overcoming Therapeutic Inertia with Inhaled Insulin TherapyThomas C Blevins, Steve V Edelman
Nature Clinical Practice. Endocrinology & Metabolism|April 25, 2007
Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?Steve V Edelman, Satish Garg, Orville G Kolterman
Diabetes Care|November 22, 2014
Response to comment on Edelman et al. AUTONOMY: the first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetes. Diabetes Care 2014;37:2132-2140Steve V Edelman, Rong Liu, Jennal Johnson, et al.
Diabetes Care|April 19, 2014
AUTONOMY: the first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetesSteve V Edelman, Rong Liu, Jennal Johnson, et al.
The Diabetes Educator|December 14, 2018
Reference Guide for Integrating Continuous Glucose Monitoring Into Clinical PracticeDavida F Kruger, Steve V Edelman, Deborah A Hinnen, et al.
Diabetes Technology & Therapeutics|February 1, 2026
Dosing Afrezza: It's Not that ComplicatedSteve V Edelman, Thomas C Blevins, Christopher G Parkin, et al.
Diabetes, Obesity & Metabolism|May 29, 2025
Risk of new-onset type 1 diabetes in individuals with celiac disease and thyroid disease-An observational studySteve V Edelman, Daniel Agardh, Nancy Cui, et al.
Diabetes, Obesity & Metabolism|October 20, 2022
Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trialTadej Battelino, Thomas Danne, Steve V Edelman, et al.
Pageof 1